Herein, our analysis and experimental verification demonstrated that ATP1A2 is lowly expressed in BLCA, and overexpression of ATP1A2 was associated with unfavorable outcomes in BLCA patients. This evidence concerns the gene ATP1A2 and bladder transitional cell carcinoma.